Narrow search
Showing 1 - 10 of 3,377
Cover Image
Can Operation Warp Speed Serve as a Model for Accelerating Innovations Beyond COVID Vaccines?
Hoyt, Kendall; Snyder, Christopher M.; Stapp, Alec - National Bureau of Economic Research - 2024
Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...
Persistent link: https://www.econbiz.de/10015056157
Cover Image
Preparing for a Pandemic : Accelerating Vaccine Availability
Ahuja, Amrita; Athey, Susan; Baker, Arthur; Budish, Eric B. - National Bureau of Economic Research - 2021
Vaccinating the world's population quickly in a pandemic has enormous health and economic benefits. We analyze the …
Persistent link: https://www.econbiz.de/10012482707
Cover Image
Does Disease Cause Vaccination? Disease Outbreaks and Vaccination Response
Oster, Emily - 2016
Childhood vaccinations are an important input to disease prevention, but vaccination rates have declined over the last … impact. Anecdotal evidence on disease outbreaks suggests that they may prompt vaccination behavior. I use newly compiled data … vaccination rate increases among children at school entry following an outbreak in the year prior. A large outbreak in the county …
Persistent link: https://www.econbiz.de/10012456213
Cover Image
Creating Markets for New Vaccines Part II : Design Issues
Kremer, Michael - 2000
Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed. For these programs to spur research, potential vaccine developers must believe that the sponsor will not...
Persistent link: https://www.econbiz.de/10012471044
Cover Image
Financing Vaccines for Global Health Security
Vu, Jonathan T. - 2020
Recent outbreaks of infectious pathogens such as Zika, Ebola, and COVID-19 have underscored the need for the dependable availability of vaccines against emerging infectious diseases (EIDs). The cost and risk of R&D programs and uniquely unpredictable demand for EID vaccines have discouraged...
Persistent link: https://www.econbiz.de/10012481795
Cover Image
Reserve System Design for Allocation of Scarce Medical Resources in a Pandemic : Some Perspectives from the Field
Pathak, Parag A.; Persad, Govind; Sönmez, Tayfun; … - National Bureau of Economic Research - 2022
The Covid-19 pandemic has brought renewed attention to rationing guidelines for scarce medical resources. This paper describes the benefits of using a reserve system over a priority system in operationalizing compromises between certain ethical goals. In the last two years, more than a dozen...
Persistent link: https://www.econbiz.de/10013210092
Cover Image
Pandemics, Vaccines and Corporate Earnings
Hong, Harrison - 2020
We estimate a model of damage to corporate earnings from COVID-19. An unexpected pandemic lowers current earnings due to costly mitigation and reduces growth rates. Damage depends on the expected arrival of a vaccine that reverts earnings to normal. Using this model, we infer from analysts'...
Persistent link: https://www.econbiz.de/10012481132
Cover Image
A Cost/Benefit Analysis of Clinical Trial Designs for COVID-19 Vaccine Candidates
Berry, Donald A. - 2020
We compare and contrast the expected duration and number of infections and deaths averted among several designs for clinical trials of COVID-19 vaccine candidates, including traditional randomized clinical trials and adaptive and human challenge trials. Using epidemiological models calibrated to...
Persistent link: https://www.econbiz.de/10012482101
Cover Image
The Impact of Vaccines and Behavior on U.S. Cumulative Deaths from COVID-19
Atkeson, Andrew - National Bureau of Economic Research - 2023
The CDC reports that 1.13 million Americans have died of COVID-19 through June of 2023. I use a model of the impact over the past three years of vaccines and private and public behavior to mitigate disease transmission during the COVID-19 pandemic in the United States to address two questions....
Persistent link: https://www.econbiz.de/10014337759
Cover Image
Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development
Glennerster, Rachel; Kelly, Thomas; McMahon, Claire T.; … - National Bureau of Economic Research - 2024
A booster of the COVID-19 vaccine targeting the prevailing Omicron variant did not become available in the United States until a year after the variant was first detected. This pattern of developing, testing, and distributing a variant-specific booster may become the default response to further...
Persistent link: https://www.econbiz.de/10014468259